Jounce Therapeutics (JNCE) Tops Q3 EPS by 2c

Jounce Therapeutics (NASDAQ: JNCE) reported Q3 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62).

For earnings history and earnings-related data on Jounce Therapeutics (JNCE) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• Deutsche Bank monitors UK auto sales as Chinese exports grow